My Total Health Partners with the American College of Gastroenterology to Provide Scientific and Clinical Education to Patients Suffering from GI Symptoms

Collaboration will expand MyGiHealth’s Learning and Treatment Centers as well as provide greater access to providers across the full spectrum of gastroenterology Salem, Mass. (October 26, 2021) – My Total Health Inc., in strategic partnership with Commonwealth Diagnostics International, Inc. (CDI), announced it will expand education content available via its MyGiHealth application with a new…

Commonwealth Diagnostics International, Inc. Cofounders Honored Amongst Peers in Business and Healthcare

Salem, Mass. – June 29, 2021 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce that two of its cofounders, Craig Strasnick and Gray W. Rifkin, were honored recently amongst their peers in both business and healthcare. Strasnick, CDI President and CEO, was named to the Forbes Next 1000 list of upstart entrepreneurs redefining…

Commonwealth Diagnostics International, Inc. (CDI) announces expanded industry and research partnerships in the United States and abroad

Salem, Mass. – May 21, 2021 – Over the past 10 years, Commonwealth Diagnostics International, Inc. (CDI) leadership team has worked closely with industry stakeholders to support the gastroenterology (GI) community. Today, CDI is pleased to announce it has expanded partnerships with several industry and research partners both in the United States and abroad, including…

IBSchek® Granted PLA Code from AMA; CDI to Now Accept Insurance, Providing More Patients At-Home Access

Maximum out-of-pocket cost for first clinically validated IBS blood test also to be reduced, making it the most affordable IBS diagnostic test on the market Salem, Mass. – February 3, 2021 – For too long millions of patients requiring a simple and reliable blood test for Irritable Bowel Syndrome (IBS) have been met with soaring…

CDI Introduces Validated At-Home Collection Kit for IBSchek®

The Improved Sample Collection Method Expands Access to the Blood Test for Diagnosing DiarrheaPredominant and Mixed-Type Irritable Bowel Syndrome SALEM, MA February 1, 2020 – Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek®, the first clinically validated biomarker blood test for…

CDI Announces Participation in Clinical Trial with the University of Michigan

Salem, MA – January 10, 2020 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to participate in a clinical trial with the University of Michigan, one of the largest gastroenterology practices in the country and a leader in the GI community. The clinical trial, Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea (IBS-D),…

CDI Announces Participation in the U.S Department of Veterans Affairs Community Care Network

Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the U.S. Department of Veterans Affairs’ (the VA’s) Community Care Network (CCN). The CCN is the VA’s direct link with specialized community providers, like CDI, to ensure that over 9 million enrolled Veterans receive adequate choice of and access to proper, timely, and…

CDI Announces Its Participation in the Blue Cross Blue Shield of Massachusetts Network

Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the Blue Cross Blue Shield of Massachusetts Network. CDI is a diagnostic laboratory located in Salem, Massachusetts that offers a variety of products, services, and technologies that aid in the diagnosis of gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO) and Irritable…

First Clinically Validated Blood Test for Diagnosing Diarrhea-Predominant and Mixed-Type Irritable Bowel Syndrome

Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek™, the first clinically validated blood test for diarrhea-predominant and mixed-type Irritable Bowel Syndrome (IBS-D, IBS-M). CDI will officially re-launch IBSchek to the gastroenterology community at Digestive Disease Week in Washington, DC in June…

CDI Receives MDEL In Canada for Non-Invasive Diagnostic Breath Tests

Commonwealth Diagnostics International, Inc. (CDI), the leader in hydrogen and methane breath testing® for functional gastrointestinal disorders, announces its entry into the Canadian healthcare market. CDI will offer its state-of-the-art, non-invasive, functional GI diagnostic tests to the approximately five million Canadians afflicted with Irritable Bowel Syndrome (IBS)1, and millions of other patients suffering from functional…